Barclays Initiates Coverage On LivaNova with Overweight Rating, Announces Price Target of $105
Barclays analyst Christopher Pasquale initiates coverage on LivaNova (NASDAQ:LIVN) with a Overweight rating and announces Price Target of $105.
Stocks · News reference
Piper Sandler Reiterates Overweight on LivaNova, Raises Price Target to $90
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Global Bioelectronic Medicine Market Anticipates Impressive Growth Trajectory of ~10% by 2034 | DelveInsight
The global bioelectronic medicine market is projected to grow from USD 8.9 billion in 2025 to USD 21.6 billion by 2034, driven by increasing adoption of neuromodulation technologies, advances in implantable devices, AI integration, and expanding applications beyond neurological disorders. North America leads the market with 44% share, while Asia-Pacific is expected to record the fastest growth rate.
Needham Maintains Buy on LivaNova, Raises Price Target to $93
Needham analyst Mike Matson maintains LivaNova (NASDAQ:LIVN) with a Buy and raises the price target from $81 to $93.